Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
NCT06727773

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-05-06

90

Participants Needed

1

Research Sites

199 weeks

Total Duration

On this page

Sponsors

U

UNC Lineberger Comprehensive Cancer Center

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.

CONDITIONS

Official Title

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female
  • Age 18 years or older at the time of consent
  • Diagnosed with stage I-III breast cancer
  • Recommended to receive chemotherapy
  • Enrolled before the 3rd cycle of chemotherapy
  • Able to speak and understand English
Not Eligible

You will not qualify if you...

  • Allergy to memantine
  • Previous chemotherapy before the current treatment
  • Severe cognitive impairment (Blessed Orientation Memory Concentration Test Score greater than or equal to 11)
  • Heart attack in the last 6 months
  • Cardiovascular or orthopedic issues preventing exercise
  • Severe mental illness such as schizophrenia or bipolar disorder
  • Current alcohol or drug abuse
  • Unable to swallow capsules
  • Creatinine clearance (CrCl) less than or equal to 5 mL/min

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

Chapel Hill, North Carolina, United States, 27599

Actively Recruiting

Loading map...

Research Team

A

Ashley M Hanson

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here